Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Research & Development (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Research & Development data on record, last reported at $34.8 million in Q4 2023.

  • For Q4 2023, Research & Development changed N/A year-over-year to $34.8 million; the TTM value through Dec 2023 reached $148.2 million, changed N/A, while the annual FY2024 figure was $142.9 million, 3.55% down from the prior year.
  • Research & Development reached $34.8 million in Q4 2023 per CGEM's latest filing, up from $33.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $52.1 million in Q1 2023 and bottomed at $4.2 million in Q1 2020.
  • Average Research & Development over 4 years is $21.4 million, with a median of $18.8 million recorded in 2020.
  • The widest YoY moves for Research & Development: up 197.51% in 2021, down 5.75% in 2021.
  • A 4-year view of Research & Development shows it stood at $16.6 million in 2020, then rose by 25.55% to $20.9 million in 2021, then grew by 26.5% to $26.4 million in 2022, then soared by 31.95% to $34.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Research & Development were $34.8 million in Q4 2023, $33.8 million in Q3 2023, and $27.4 million in Q2 2023.